Small molecules for regenerative medicine
In this episode, we discuss how new insights into stem cell biology are leading to novel therapeutics in regenerative medicine beyond cell therapy.
List view / Grid view
In this episode, we discuss how new insights into stem cell biology are leading to novel therapeutics in regenerative medicine beyond cell therapy.
We had the privilege of interviewing Brian Culley, CEO of Lineage Cell Therapeutics. He discusses how Lineage’s pluripotent stem cell platform is extraordinarily advantageous, details two early-stage programmes addressing auditory and vision disorders and reveals how Lineage is choosing to target conditions that will make a real difference.
The world’s first generation of human BBB organoids from hPSCs accurately replicated features of cerebral cavernous malformation.
Culture conditions during embryoid body formation can be enhanced to gain glia-associated proteins and neural network activity.
Researchers uncover a genetic pathway of parietal cell development, which will enable a better understanding of stomach conditions.
The new study provides proof of principle that functional liver cells can be grown in a different species, offering a potential solution to transplant shortage.
Researchers found that genetic depletion of cyclophilin A results in stem cells distinctively lacking intrinsically disordered proteins.
Induced NPCs facilitate the creation of patient-specific organoid models and improve identification of nephron targeted drugs.
A synthetic antibody selectively activates the Wnt signalling pathway and directs stem cells to differentiate into neurons.
In this episode, we discuss the current advantages and limitations of using organoids, as well as where the field is heading.
Injections of cardiac spheroids into primate ventricles improved left ventricular ejection after four weeks.
CRISPR has transformed gene editing, but still presents challenges in hard-to-transfect cells, such as pluripotent stem cells and primary cells.1 The key to obtaining successful transfection in these cells lies in innovative workflows. Here Georges Müller, CEO and cofounder of SEED Biosciences, shares his perspective on why focusing on editing…
Transplant recipients of hematopoietic stem cells with a hereditary version of AD developed the disease at an accelerated rate.
Stem-cell based blastocyst models have enabled scientists to redefine the molecular signature and timing of the onset of gastrulation.
The discovery of two proteins that effectively mature hiPSCs into endothelial cells may have a range of research and clinical benefits.